Keytruda may be a miracle cancer drug By Steve|2018-07-29T00:09:41+12:00July 29th, 2018|All, Funding, IMMUNOTHERAPY| Read More 0
Vyriad Expands Phase 1 Trial to Test Voyager-V1 By Steve|2018-07-28T06:11:12+12:00July 28th, 2018|All, IMMUNOTHERAPY, Media, TRIALS| Read More 0
Rare Cancers Australia 33 Million Win By Steve|2018-07-24T01:21:48+12:00July 24th, 2018|All, Funding| Read More 0
Cycling in the Chemo By Steve|2018-09-28T06:54:40+12:00July 18th, 2018|All, Chemotherapy| Read More 0
Bile Duct Cancer – How it develops and how to prevent it By Steve|2018-04-24T07:16:01+12:00April 23rd, 2018|All, Prevention| Read More 0
Capecitabine Improves Survival of Patients with Rare Cancer by Almost a Quarter By Steve|2018-04-24T07:17:30+12:00April 23rd, 2018|All, Chemotherapy| Read More 0
CC with Andrew Clacher By Steve|2019-07-18T07:05:12+12:00February 12th, 2018|All, PATIENT| Read More 0
Immunotherapy achieves dramatic results By Steve|2018-01-11T07:53:44+13:00January 11th, 2018|All, IMMUNOTHERAPY| Read More 0
Can Bile Duct Cancer’s follow the Melanoma lead By Steve|2018-01-11T07:54:34+13:00January 11th, 2018|All, IMMUNOTHERAPY| Read More 0
Bayer enters the immunotherapy race By Steve|2017-11-26T02:13:17+13:00November 25th, 2017|All, IMMUNOTHERAPY| Read More 0